Last reviewed · How we verify
DSM265 ymg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
DSM265 ymg (DSM265 ymg) — Medicines for Malaria Venture.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DSM265 ymg TARGET | DSM265 ymg | Medicines for Malaria Venture | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DSM265 ymg CI watch — RSS
- DSM265 ymg CI watch — Atom
- DSM265 ymg CI watch — JSON
- DSM265 ymg alone — RSS
Cite this brief
Drug Landscape (2026). DSM265 ymg — Competitive Intelligence Brief. https://druglandscape.com/ci/dsm265-ymg. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab